382 related articles for article (PubMed ID: 23335963)
1. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
[TBL] [Abstract][Full Text] [Related]
2. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
3. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
[TBL] [Abstract][Full Text] [Related]
4. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
5. ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.
Li W; Chen Q; Gao W; Zeng H
Pharmazie; 2022 Sep; 77(7):224-229. PubMed ID: 36199183
[TBL] [Abstract][Full Text] [Related]
6. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
7. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
8. CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2.
Xiao G; Wang X; Yu Y
Cell Physiol Biochem; 2017; 43(2):840-851. PubMed ID: 28954272
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
10. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
[TBL] [Abstract][Full Text] [Related]
11. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
12. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
[TBL] [Abstract][Full Text] [Related]
14. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
Maftouh M; Avan A; Funel N; Frampton AE; Fiuji H; Pelliccioni S; Castellano L; Galla V; Peters GJ; Giovannetti E
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):384-93. PubMed ID: 24940696
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
16. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
Liu Q; Song C; Li J; Liu M; Fu L; Jiang J; Zeng Z; Zhu H
Med Oncol; 2022 Jun; 39(9):124. PubMed ID: 35716217
[TBL] [Abstract][Full Text] [Related]
17. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
18. SYNCRIP, a new player in pri-let-7a processing.
Chen Y; Chan J; Chen W; Li J; Sun M; Kannan GS; Mok YK; Yuan YA; Jobichen C
RNA; 2020 Mar; 26(3):290-305. PubMed ID: 31907208
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
Rüstem DG; Atay S; Aydin HH; Ak H
Anticancer Agents Med Chem; 2021 Oct; 21(16):2204-2215. PubMed ID: 33397269
[TBL] [Abstract][Full Text] [Related]
20. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
